Novartis bets priority review voucher on its next big multiple sclerosis drug — eyes US, EU approvals in ’19

10 October 2018

Source Endpoints News: One of Novartis’ top late-stage candidates for multiple sclerosis is now under review on both sides of the Atlantic.

Having stoked enthusiasm for siponimod through a solid Phase III data package, the Swiss drugmaker traded in a priority review voucher at the FDA for an expedited action date around March of next year. The EMA decision, meanwhile, will likely come in late 2019.

If Novartis appears upbeat, it’s for obvious reasons.  Read on. 

 One of Novartis’ top late-stage candidates for multiple sclerosis is now under review on both sides of the Atlantic.

Having stoked enthusiasm for siponimod through a solid Phase III data package, the Swiss drugmaker traded in a priority review voucher at the FDA for an expedited action date around March of next year. The EMA decision, meanwhile, will likely come in late 2019.

If Novartis appears upbeat, it’s for obvious reasons.

Blog categories: 

Category

Archive